Nectar Lifescience Ltd
NECLIFE NSE
Nectar Lifescience Ltd
HealthcareNSE: NECLIFE BSE: 532649 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹207 Cr
Volatility
Moderate
P/E Ratio
-0.8
EBITDA
₹-296 Cr
Return on Equity
-11.89%
Debt to Equity
0
Book Value
₹29.97
52W High
₹22.4
52W Low
₹9.3
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Nectar Lifescience Ltd insights
42 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.36 times its book value
Weaknesses
4- Company has low interest coverage ratio.
- Company has a low return on equity of -12.3% over last 3 years.
- Contingent liabilities of Rs.269 Cr.
- Promoter holding has decreased over last 3 years: -3.96%
Growth Rate
Revenue Growth
-100.00% ↘
Net Income Growth
184.45% ↗
Cash Flow Change
-305.81% ↘
ROE
-2629.79% ↘
ROCE
-198.03% ↘
EBITDA Margin (Avg.)
-100.00% ↘
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 394 | 398 | 452 | 441 | 359 | 6 | 0 | 0 | 5 | 1 | 0 | 1 | 0 |
| Expenses | 359 | 371 | 410 | 393 | 319 | 6 | 0 | 0 | 6 | 0 | 2 | 59 | 28 |
| Operating Profit | 36 | 27 | 42 | 48 | 40 | -1 | 0 | 0 | -1 | 1 | -2 | -57 | -27 |
| OPM % | 9% | 7% | 9% | 11% | 11% | -10% | -500% | -500% | -16% | 77% | — | -4437% | -6198% |
| Other Income | 0 | 11 | 0 | 1 | 1 | 7 | 8 | -130 | -62 | -176 | 35 | -24 | 3 |
| Interest | 18 | 21 | 25 | 24 | 20 | 0 | 0 | 0 | 0 | 0 | 30 | 6 | 0 |
| Depreciation | 15 | 15 | 15 | 15 | 15 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| PBT | 3 | 2 | 2 | 11 | 5 | 5 | 8 | -130 | -64 | -176 | 3 | -88 | -24 |
| Tax % | 41% | 38% | 36% | 95% | 40% | -2% | 2% | 0% | -1% | 0% | -339% | -22% | -37% |
| Net Profit | 2 | 1 | 2 | 1 | 3 | 6 | 8 | -130 | -63 | -176 | 14 | -68 | -15 |
| EPS in Rs | 0.08 | 0.05 | 0.07 | 0.03 | 0.13 | 0.25 | 0.35 | -5.8 | -2.82 | -7.85 | 0.64 | -3.5 | -0.79 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,638 | 1,674 | 1,635 | 1,874 | 2,779 | 2,363 | 1,541 | 1,665 | 1,520 | 1,682 | 1,664 | 0 | 2 |
| Expenses | 1,371 | 1,436 | 1,411 | 1,638 | 2,514 | 2,143 | 1,432 | 1,507 | 1,467 | 1,530 | 1,694 | 8 | 88 |
| Operating Profit | 267 | 239 | 224 | 236 | 264 | 220 | 109 | 159 | 53 | 152 | -30 | -8 | -86 |
| OPM % | 16% | 14% | 14% | 13% | 10% | 9% | 7% | 10% | 3.5% | 9% | -1.8% | -2920% | -3520% |
| Other Income | 20 | 6 | 23 | 6 | 6 | 4 | -22 | 11 | 43 | 15 | 5 | -279 | -162 |
| Interest | 126 | 123 | 117 | 115 | 148 | 126 | 112 | 79 | 79 | 87 | 75 | 36 | 36 |
| Depreciation | 77 | 57 | 62 | 64 | 63 | 61 | 60 | 57 | 59 | 61 | 62 | 0 | 0 |
| PBT | 85 | 64 | 67 | 63 | 59 | 37 | -85 | 34 | -42 | 18 | -162 | -323 | -285 |
| Tax % | 22% | 15% | 18% | 17% | 19% | 15% | -14% | 26% | -43% | 73% | -30% | -9% | — |
| Net Profit | 66 | 54 | 55 | 52 | 48 | 32 | -73 | 25 | -24 | 5 | -114 | -293 | -245 |
| EPS in Rs | 2.95 | 2.42 | 2.47 | 2.33 | 2.12 | 1.42 | -3.27 | 1.12 | -1.08 | 0.22 | -5.07 | -15.08 | -11.5 |
| Div. Payout % | 3% | 4% | 2% | 2% | 2% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 19 |
| Reserves | 936 | 932 | 984 | 1,036 | 1,083 | 1,114 | 1,040 | 1,065 | 1,042 | 1,047 | 934 | 563 |
| Borrowings | 925 | 962 | 878 | 955 | 903 | 779 | 903 | 860 | 754 | 636 | 582 | 0 |
| Other Liabilities | 628 | 640 | 696 | 710 | 696 | 718 | 423 | 443 | 371 | 486 | 509 | 39 |
| Total Liabilities | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 | 622 |
| Fixed Assets | 934 | 906 | 881 | 852 | 825 | 785 | 772 | 723 | 662 | 643 | 633 | 105 |
| CWIP | 91 | 99 | 102 | 100 | 100 | 115 | 99 | 85 | 78 | 66 | 57 | 0 |
| Investments | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 13 |
| Other Assets | 1,485 | 1,551 | 1,597 | 1,771 | 1,780 | 1,733 | 1,517 | 1,582 | 1,449 | 1,482 | 1,357 | 504 |
| Total Assets | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 | 622 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 144 | 169 | 199 | 65 | 239 | 285 | 21 | 95 | 134 | 225 | 169 | -349 |
| Investing | -60 | -77 | -18 | -29 | -26 | -33 | -29 | 17 | 52 | -17 | -42 | 1,208 |
| Financing | -61 | -89 | -204 | -40 | -201 | -252 | 11 | -119 | -186 | -205 | -128 | -767 |
| Net Cash Flow | 23 | 3 | -23 | -4 | 12 | 0 | 4 | -8 | 0 | 2 | -1 | 93 |
| Free Cash Flow | 64 | 87 | 174 | 32 | 204 | 249 | -10 | 110 | 183 | 195 | 126 | -341 |
| CFO/OP | 56 | 74 | 92 | 33 | 96 | 134 | 23 | 60 | 252 | 148 | -574 | 4,132 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 99 | 107 | 112 | 119 | 73 | 61 | 89 | 98 | 67 | 82 | 76 | — |
| Inventory Days | 253 | 260 | 270 | 226 | 151 | 192 | 185 | 197 | 212 | 215 | 184 | — |
| Days Payable | 146 | 154 | 167 | 142 | 80 | 104 | 108 | 112 | 100 | 127 | 117 | — |
| Cash Conversion Cycle | 207 | 213 | 215 | 203 | 145 | 150 | 166 | 182 | 179 | 170 | 143 | — |
| Working Capital Days | 40 | 41 | 45 | 67 | 46 | 53 | 6 | 73 | 77 | 63 | 43 | — |
| ROCE % | 11% | 10% | 10% | 9% | 10% | 8% | 3% | 5% | 0% | 6% | -5% | 0% |
Documents
1
Disclosure As Per Regulation 30 Of The Securities And Exchange Of Board Of India (LODR) Regulations, 2015
28 Apr - Income tax objections for AY 2017-18 decided in company’s favor; matter fully concluded. 28 Apr - Income tax objections for AY 2017-18 decided in company’s favor; matter fully concluded.
2
Update On Slump Sale
28 Apr - Capnest slump sale completion extended to on or before July 31, 2026. 28 Apr - Capnest slump sale completion extended to on or before July 31, 2026.
3
Disclosure As Per Regulation 30 Of The Securities And Exchange Of Board Of India (LODR) Regulations, 2015
28 Apr - Income tax objections for AY 2017-18 decided in company’s favor; matter fully concluded. 28 Apr - Income tax objections for AY 2017-18 decided in company’s favor; matter fully concluded.
4
Update On Slump Sale
28 Apr - Capnest slump sale completion extended to on or before July 31, 2026. 28 Apr - Capnest slump sale completion extended to on or before July 31, 2026.
5
Compliances-Reg.24(A)-Annual Secretarial Compliance
18 Apr - Secretarial compliance report for FY2026 notes minor delays in results/meeting notices and two fines. 18 Apr - Secretarial compliance report for FY2026 notes minor delays in results/meeting notices and two fines.
Frequently Asked Questions about Nectar Lifescience Ltd
What does Nectar Lifescience Ltd do?
Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations[1]
Where is Nectar Lifescience Ltd (NECLIFE) listed?
Nectar Lifescience Ltd is listed on the Indian stock exchanges. It is listed on NSE: NECLIFE and BSE: 532649. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Nectar Lifescience Ltd belong to?
Nectar Lifescience Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Nectar Lifescience Ltd?
Nectar Lifescience Ltd has a market capitalisation of approximately ₹207.47 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Nectar Lifescience Ltd?
The Price-to-Earnings (PE) ratio of Nectar Lifescience Ltd is -0.80. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Nectar Lifescience Ltd?
Over the past 52 weeks, Nectar Lifescience Ltd has traded between a low of ₹9.3 and a high of ₹22.4. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Nectar Lifescience Ltd?
Nectar Lifescience Ltd has a Return on Equity (ROE) of -11.89%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Nectar Lifescience Ltd on Tapetide?
On Tapetide, you can view Nectar Lifescience Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations[1]
Website neclife.com
CEO Mr. Sanjiv Goyal
Employees 1,786
Listed 2005-07-18
Face Value ₹ 1
Issued Size 22,42,60,970